CTLA4 and melanoma: In the past decade, several new systemic drugs have been introduced, including IT with checkpoint inhibitors such as anti-CTLA4 antibodies [ipilimumab (IPI)]94,95, anti-PD1 antibodies (nivolumab and pembrolizumab)96,97, or a combination of these drugs98, and promising results have been observed in patients with melanoma.